Sickle cell anemia (SCA) is associated with a hypercoagulable state. Increased platelet activation is reported in SCA and SCA platelets may present augmented adhesion to the vascular endothelium, potentially contributing to the vaso-occlusive process. We sought to observe the effects of platelets (PLTs) from healthy control (CON) individuals and SCA individuals on endothelial activation, in vitro. Human umbilical vein endothelial cells (HUVEC) were cultured, in the presence, or not, of washed PLTs from CON or steady-state SCA individuals. Supernatants were reserved for cytokine quantification, and endothelial adhesion molecules (EAM) were analyzed by flow cytometry; gene expressions of ICAM1 and genes of the NF-kB pathway were analyzed by qPCR. SCA PLTs were found to be more inflammatory, displaying increased adhesive properties, an increased production of IL-1β and a tendency towards elevated expressions of P-selectin and activated αIIbβ 3. Following culture in the presence of SCA PLTs, HUVEC presented significant augmentations in the expressions of the EAM, ICAM-1 and E-selectin, as well as increased IL-8 production and increased ICAM1 and NFKB1 (encodes p50 subunit of NF-κB) gene expressions. Interestingly, transwell inserts abolished the effects of SCA PLTs on EAM expression. Furthermore, an inhibitor of the NF-κB pathway, BAY 11-7082, also prevented the induction of EAM expression on the HUVEC surface by SCA PLTs. In conclusion, we find further evidence to indicate that platelets circulate in an activated state in sickle cell disease and are capable of stimulating endothelial cell activation. This effect appears to be mediated by direct contact, or even adhesion, between the platelets and endothelial cells and via NFκB-dependent signaling. As such, activated platelets in SCD may contribute to endothelial activation and, therefore, to the vaso-occlusive process. Results provide further evidence to support the use of anti-platelet approaches in association with other therapies for SCD. © 2014 Proença-Ferreira et al.92 Stuart, M.J., Nagel, R.L., Sickle-cell disease (2004) Lancet, 364 (9442), pp. 1343-1360. , DOI 10.1016/S0140-6736(04)17192-4, PII S0140673604171924Conran, N., Franco-Penteado, C.F., Costa, F.F., Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion (2009) Hemoglobin, 33, pp. 1-16Adams, R.J., Big strokes in small persons (2007) Arch Neurol, 64, pp. 1567-1574Sparkenbaugh, E., Pawlinski, R., Interplay between coagulation and vascular inflammation in sickle cell disease (2013) Br J HaematolNoubouossie, D.C., Le, P.Q., Rozen, L., Ziereisen, F., Willems, D., Thrombin generation in children with sickle cell disease: Relationship with age, hemolysis, transcranial doppler velocity, and hydroxyurea treatment (2013) Eur J HaematolPeters, M., Plaat, B.E.C., Ten, C.H., Wolters, H.J., Weening, R.S., Brandjes, D.P.M., Enhanced thrombin generation in children with sickle cell disease (1994) Thrombosis and Haemostasis, 71 (2), pp. 169-172Stuart, M.J., Setty, B.N.Y., Hemostatic alterations in sickle cell disease: Relationships to disease pathophysiology (2001) Pediatric Pathology and Molecular Medicine, 20 (1), pp. 27-46. , DOI 10.1080/15227950150502529Francis Jr., R.B., Elevated fibrin D-dimer fragment in sickle cell anemia: Evidence for activation of coagulation during the steady state as well as in painful crisis (1989) Haemostasis, 19, pp. 105-111Setty, B.N., Key, N.S., Rao, A.K., Gayen-Betal, S., Krishnan, S., Tissue factor-positive monocytes in children with sickle cell disease: Correlation with biomarkers of haemolysis (2012) Br J Haematol, 157, pp. 370-380Colella, M.P., De Paula, E.V., Conran, N., Machado-Neto, J.A., Annicchino-Bizzacchi, J.M., Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia (2012) J Thromb Haemost, 10, pp. 1967-1970Solovey, A., Gui, L., Key, N.S., Hebbel, R.P., Tissue factor expression by endothelial cells in sickle cell anemia (1998) Journal of Clinical Investigation, 101 (9), pp. 1899-1904Kenny, M.W., George, A.J., Stuart, J., Platelet hyperactivity in sickle-cell disease: A consequence of hyposplenism (1980) Journal of Clinical Pathology, 33 (7), pp. 622-625Wun, T., Paglieroni, T., Rangaswami, A., Franklin, P.H., Welborn, J., Cheung, A., Tablin, F., Platelet activation in patients with sickle cell disease (1998) British Journal of Haematology, 100 (4), pp. 741-749. , DOI 10.1046/j.1365-2141.1998.00627.xProenca-Ferreira, R., Franco-Penteado, C.F., Traina, F., Saad, S.T., Costa, F.F., Increased adhesive properties of platelets in sickle cell disease: Roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity (2010) Br J Haematol, 149, pp. 280-288Triadou, P., Fonty, E., Ambrosio, A.S., Cottat, M.C., Girot, R., Cornu, P., Platelet function in sickle cell disease during steady state (1990) Nouvelle Revue Francaise d'Hematologie, 32 (2), pp. 137-142Mehta, P., Mehta, J., Abnormalities of platelet aggregation in sickle cell disease (1980) Journal of Pediatrics, 96 (2), pp. 209-213Tomer, A., Platelet activation as a marker for in vivo prothrombotic activity: Detection by flow cytometry (2004) J Biol Regul Homeost Agents, 18, pp. 172-177Lee, S.P., Ataga, K.I., Orringer, E.P., Phillips, D.R., Parise, L.V., Biologically active CD40 ligand is elevated in sickle cell anemia: Potential role for platelet-mediated inflammation (2006) Arteriosclerosis, Thrombosis, and Vascular Biology, 26 (7), pp. 1626-1631. , DOI 10.1161/01.ATV.0000220374.00602.a2, PII 0004360520060700000035Garrido, V.T., Proenca-Ferreira, R., Dominical, V.M., Traina, F., Bezerra, M.A., Elevated plasma levels and platelet-associated expression of the prothrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease (2012) Br J Haematol, 158, pp. 788-797Browne, P.V., Mosher, D.F., Steinberg, M.H., Hebbel, R.P., Disturbance of plasma and platelet thrombospondin levels in sickle cell disease (1996) American Journal of Hematology, 51 (4), pp. 296-301. , DOI 10.1002/(SICI)1096-8652(199604)51:4<296::AIDNovelli, E.M., Kato, G.J., Ragni, M.V., Zhang, Y., Hildesheim, M.E., Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates (2012) Am J Hematol, 87, pp. 326-330Tomer, A., Harker, L.A., Kasey, S., Eckman, J.R., Thrombogenesis in sickle cell disease (2001) Journal of Laboratory and Clinical Medicine, 137 (6), pp. 398-407. , DOI 10.1067/mlc.2001.115450Wun, T., Paglieroni, T., Tablin, F., Welborn, J., Nelson, K., Cheung, A., Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia (1997) Journal of Laboratory and Clinical Medicine, 129 (5), pp. 507-516Setty, B.N., Rao, A.K., Stuart, M.J., Thrombophilia in sickle cell disease: The red cell connection (2001) Blood, 98, pp. 3228-3233Setty, B.N.Y., Kulkarni, S., Rao, A.K., Stuart, M.J., Fetal hemoglobin in sickle cell disease: Relationship to erythrocyte phosphatidylserine exposure and coagulation activation (2000) Blood, 96 (3), pp. 1119-1124Polanowska-Grabowska, R., Wallace, K., Field, J.J., Chen, L., Marshall, M.A., P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease (2010) Arterioscler Thromb Vasc Biol, 30, pp. 2392-2399Wun, T., Cordoba, M., Rangaswami, A., Cheung, A.W., Paglieroni, T., Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease (2002) Clinical and Laboratory Haematology, 24 (2), pp. 81-88. , DOI 10.1046/j.1365-2257.2002.00433.xVillagra, J., Shiva, S., Hunter, L.A., Machado, R.F., Gladwin, M.T., Kato, G.J., Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin (2007) Blood, 110 (6), pp. 2166-2172. , http://bloodjournal.hematologylibrary.org/cgi/reprint/110/6/2166, DOI 10.1182/blood-2006-12-061697Sakamoto, T.M., Canalli, A.A., Traina, F., Franco-Penteado, C.F., Gambero, S., Altered red cell and platelet adhesion in hemolytic diseases: Hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria and sickle cell disease (2013) Clin BiochemFinco, T.S., Baldwin, A.S., Mechanistic aspects of NF-kappa B regulation: The emerging role of phosphorylation and proteolysis (1995) Immunity, 3, pp. 263-272Barnes, P.J., Karin, M., Nuclear factor-kappaB - A pivotal transcription factor in chronic inflammatory diseases (1997) New England Journal of Medicine, 336 (15), pp. 1066-1071. , DOI 10.1056/NEJM199704103361506Epinat, J.C., Gilmore, T.D., Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway (1999) Oncogene, 18, pp. 6896-6909Hidalgo, A., Chang, J., Jang, J.E., Peired, A.J., Chiang, E.Y., Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury (2009) Nat Med, 15, pp. 384-391Laffont, B., Corduan, A., Ple, H., Duchez, A.C., Cloutier, N., Activated platelets can deliver mRNA regulatory Ago2.MicroRNA complexes to endothelial cells via microparticles (2013) Blood, 122, pp. 253-261Belcher, J.D., Marker, P.H., Weber, J.P., Hebbel, R.P., Vercellotti, G.M., Activated monocytes in sickle cell disease: Potential role in the activation of vascular endothelium and vaso-occlusion (2000) Blood, 96, pp. 2451-2459Charneski, L., Congdon, H.B., Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: A review of the literature (2010) Am J Health Syst Pharm, 67, pp. 895-900Osamo, N.O., Photiades, D.P., Famodu, A.A., Therapeutic effect of aspirin in sickle cell anaemia (1981) Acta Haematologica, 66 (2), pp. 102-107Chaplin Jr., H., Monroe, M.C., Malecek, A.C., Morgan, L.K., Michael, J., Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises (1989) East Afr Med J, 66, pp. 574-584Chaplin Jr., H., Alkjaersig, N., Fletcher, A.P., Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises (1980) Thrombosis and Haemostasis, 43 (3), pp. 218-221Wun, T., Soulieres, D., Frelinger, A.L., Krishnamurti, L., Novelli, E.M., A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease (2013) J Hematol Oncol, 6, p. 17Jakubowski, J.A., Zhou, C., Small, D.S., Winters, K.J., Lachno, D.R., A Phase 1 Study of Prasugrel in Patients with Sickle Cell Disease: Pharmacokinetics and Effects on ex Vivo Platelet Reactivity (2013) Br J Clin Pharmacol, 75, pp. 1433-1444Lee, S.P., Ataga, K.I., Zayed, M., Manganello, J.M., Orringer, E.P., Phillips, D.R., Parise, L.V., Phase I study of eptifibatide in patients with sickle cell anaemia (2007) British Journal of Haematology, 139 (4), pp. 612-620. , DOI 10.1111/j.1365-2141.2007.06787.xDesai, P.C., Brittain, J.E., Jones, S.K., McDonald, A., Wilson, D.R., A Pilot Study of Eptifibatide for Treatment of Acute Pain Episodes in Sickle Cell Disease (2013) Thromb Res, 132, pp. 341-345